The results of our joint research with Prof. Handa and colleagues at Tokyo Medical University have been published in Scientific Reports. This is the result of a genetic screening to elucidate the mechanism of anticancer activity of thalidomide derivatives against multiple myeloma, and revealed that the subcellular localization of thalidomide target protein cereblon (CRBN) plays an important role in the drug efficacy of thalidomide derivatives.